TY - JOUR
T1 - The replacement of the 2-methoxy substituent of N-((6,6-diphenyl-1,4-dioxan-2-yl)methyl)-2-(2-methoxyphenoxy)ethan-1-amine improves the selectivity for 5-HT1Areceptor over α1-adrenoceptor and D2-like receptor subtypes
AU - Del Bello, Fabio
AU - Bonifazi, Alessandro
AU - Giannella, Mario
AU - Giorgioni, Gianfabio
AU - Piergentili, Alessandro
AU - Petrelli, Riccardo
AU - Cifani, Carlo
AU - Micioni Di Bonaventura, Maria Vittoria
AU - Keck, Thomas M.
AU - Mazzolari, Angelica
AU - Vistoli, Giulio
AU - Cilia, Antonio
AU - Poggesi, Elena
AU - Matucci, Rosanna
AU - Quaglia, Wilma
N1 - Publisher Copyright:
© 2016 Elsevier Masson SAS
PY - 2017
Y1 - 2017
N2 - N-((6,6-diphenyl-1,4-dioxan-2-yl)methyl)-2-(2-methoxyphenoxy)ethan-1-amine (3) is a potent 5-HT1Areceptor and α1d-adrenoceptor (α1d-AR) ligand. Analogues 5–10 were rationally designed and prepared to evaluate whether electronic and/or lipophilic properties of substituents in the ortho position of its phenoxy moiety exert any favorable effects on the affinity/activity at 5-HT1Areceptor and improve selectivity over α1-ARs. To rationalize the experimental observations and derive information about receptor-ligand interactions of the reported ligands, docking studies, using 5-HT1Aand α1d-AR models generated by homology techniques, and a retrospective computational study were performed. The results highlighted that proper substituents in position 2 of the phenoxy moiety of 3 selectively address the ligands toward 5-HT1Areceptor with respect to α1-ARs and D2-like receptor subtypes. Methoxymethylenoxy derivative 9 showed the best 5-HT1Aselectivity profile and the highest potency at 5-HT1Areceptor, behaving as a partial agonist. Finally, 9, tested in light/dark exploration test in mice, significantly reduced anxiety-linked behaviors. Therefore, it may be considered a lead for the design of partial agonists potentially useful in the treatment of disorders in which 5-HT1Areceptor is involved.
AB - N-((6,6-diphenyl-1,4-dioxan-2-yl)methyl)-2-(2-methoxyphenoxy)ethan-1-amine (3) is a potent 5-HT1Areceptor and α1d-adrenoceptor (α1d-AR) ligand. Analogues 5–10 were rationally designed and prepared to evaluate whether electronic and/or lipophilic properties of substituents in the ortho position of its phenoxy moiety exert any favorable effects on the affinity/activity at 5-HT1Areceptor and improve selectivity over α1-ARs. To rationalize the experimental observations and derive information about receptor-ligand interactions of the reported ligands, docking studies, using 5-HT1Aand α1d-AR models generated by homology techniques, and a retrospective computational study were performed. The results highlighted that proper substituents in position 2 of the phenoxy moiety of 3 selectively address the ligands toward 5-HT1Areceptor with respect to α1-ARs and D2-like receptor subtypes. Methoxymethylenoxy derivative 9 showed the best 5-HT1Aselectivity profile and the highest potency at 5-HT1Areceptor, behaving as a partial agonist. Finally, 9, tested in light/dark exploration test in mice, significantly reduced anxiety-linked behaviors. Therefore, it may be considered a lead for the design of partial agonists potentially useful in the treatment of disorders in which 5-HT1Areceptor is involved.
UR - http://www.scopus.com/inward/record.url?scp=84997481971&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84997481971&partnerID=8YFLogxK
U2 - 10.1016/j.ejmech.2016.09.026
DO - 10.1016/j.ejmech.2016.09.026
M3 - Article
C2 - 27662034
AN - SCOPUS:84997481971
SN - 0223-5234
VL - 125
SP - 233
EP - 244
JO - European Journal of Medicinal Chemistry
JF - European Journal of Medicinal Chemistry
ER -